Fourth Annual National General Medical Oncology Summit

Sunday, March 2, 2025

Moderator Neil Love, MD

Faculty

Thomas A Abrams, MD Prithviraj Bose, MD Natalie S Callander, MD Ramaswamy Govindan, MD Shilpa Gupta, MD Yelena Y Janjigian, MD Ahmed Omar Kaseb, MD, CMQ Samuel J Klempner, MD Andrew T Kuykendall, MD Christopher Lieu, MD Stephen V Liu, MD Thomas Martin, MD Paul E Oberstein, MD, MS Philip A Philip, MD, PhD Kanwal Raghav, MD Jonathan E Rosenberg, MD

Fourth Annual National General Medical Oncology Summit

Sunday, March 2, 2025

Co-Moderators

Maria Regina Flores, MD Lucio N Gordan, MD Maen Hussein, MD Anjan J Patel, MD Sumithra Vattigunta, MD Faye Yin, MD

Disclosures for Moderator Neil Love, MD

Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME/NCPD/ACPE activities from the following companies: AbbVie Inc, ADC Therapeutics, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Arvinas, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, Black Diamond Therapeutics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Clovis Oncology, Coherus BioSciences, CTI BioPharma, a Sobi Company, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, Exact Sciences Corporation, Exelixis Inc, Genentech, a member of the Roche Group, Genmab US Inc, Geron Corporation, Gilead Sciences Inc, GSK, Hologic Inc, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Legend Biotech, Lilly, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Mural Oncology Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Nuvalent, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Rigel Pharmaceuticals Inc, R-Pharm US, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, Stemline Therapeutics Inc, Syndax Pharmaceuticals, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, and Tesaro, A GSK Company.

Clinicians in the Meeting Room

Networked iPads are available.



Review Program Slides: Tap the Program Slides button to review speaker presentations and other program content.



Answer Survey Questions: Complete the premeeting survey.



Ask a Question: Tap Ask a Question to submit a challenging case or question for discussion. We will aim to address as many questions as possible during the program.

For assistance, please raise your hand. Devices will be collected at the conclusion of the activity.

Clinicians Attending via Zoom



Review Program Slides: A link to the program slides will be posted in the chat room at the start of the program.



Answer Survey Questions: Complete the premeeting survey.



Ask a Question: Submit a challenging case or question for discussion using the Zoom chat room.



Get CE Credit: A CE credit link will be provided in the chat room at the conclusion of the program.

For assistance, please raise your hand. Devices will be collected at the conclusion of the activity.

About the Enduring Program

- The live meeting is being video and audio recorded.
- The proceedings from this weekend will be edited and developed into an enduring web-based video/PowerPoint program. An email will be sent to all attendees when the activity is available.



 To learn more about our education programs, visit our website, <u>www.ResearchToPractice.com</u>

Make the Meeting Even More Relevant to You

Download the RTP Live app on your smartphone or tablet to access program information, including slides being presented during the program:

www.ResearchToPractice.com/RTPLiveApp



Fourth Annual National General Medical Oncology Summit

Sunday, March 2, 2025

Moderator Neil Love, MD

Faculty

Thomas A Abrams, MD Prithviraj Bose, MD Natalie S Callander, MD Ramaswamy Govindan, MD Shilpa Gupta, MD Yelena Y Janjigian, MD Ahmed Omar Kaseb, MD, CMQ Samuel J Klempner, MD Andrew T Kuykendall, MD Christopher Lieu, MD Stephen V Liu, MD Thomas Martin, MD Paul E Oberstein, MD, MS Philip A Philip, MD, PhD Kanwal Raghav, MD Jonathan E Rosenberg, MD

Fourth Annual National General Medical Oncology Summit































































































































Module 10: Colorectal Cancer

Optimizing the Care of Patients with Nonmetastatic Colorectal Cancer (CRC) — Dr Lieu

Recent Advances in the Management of Metastatic CRC — Dr Raghav

Module 10: Colorectal Cancer

Optimizing the Care of Patients with Nonmetastatic Colorectal Cancer (CRC) — Dr Lieu

Recent Advances in the Management of Metastatic CRC

— Dr Raghav



Cancer Center

NCI-DESIGNATED CONSORTIUM COMPREHENSIVE CANCER CENTER

Optimizing the Care of Patients with Nonmetastatic Colorectal Cancer (CRC)

Christopher Lieu, MD Director, GI Medical Oncology Associate Director for Clinical Research University of Colorado



Designated Comprehensive Cancer Center

Disclosures

Consulting Agreements	Amgen Inc, Pfizer Inc
Contracted Research	Genentech, a member of the Roche Group, Sanofi



Topics for Discussion

- ctDNA-based MRD monitoring in early-stage CRC
 - What have the available studies taught us about MRD testing and treatment decision making?

- Neoadjuvant checkpoint inhibition for MSI-H/dMMR resectable CRC
 - Should immunotherapy go first?



What Are the Potential Applications of ctDNA? Minimal Residual Disease Stage II Colon Cancer

DYNAMIC Study Design

Plasma Collections

Week 4 + 7 post-op

R

2:1

ACTRN12615000381583

Stage II Colon Cancer

- R0 resection
- ECOG 0 2
- Staging CT within 8 weeks
- Provision of adequate tumor tissue within 4 weeks post-op
- No synchronous colorectal cancer

Stratification Factors

- T stage (T3 vs T4)
- Type of participating center (metropolitan vs regional)

ctDNA-Guided Management

- ctDNA-Positive → Adjuvant Chemo (oxaliplatin-based or single agent FP)
- ctDNA-Negative \rightarrow Observation

ctDNA-Positive = Positive result at week 4 and/or 7

Standard Management

 Adjuvant treatment decisions based on conventional clinico-pathologic criteria

Endpoints

Primary

RFS rate at 2 years

Key Secondary

 Proportion receiving adjuvant chemo

Secondary

- RFS by ctDNA status for ctDNA-guided arm
- TTR
- OS

Surveillance:

- CEA → 3-monthly for 24M, then 6-monthly for 36M
- CT C/A/P \rightarrow 6-monthly for 24M, then at 36M


Tie et al. J Clin Oncol 40, 2022 (suppl 17; abstr LBA100)

Recurrence-Free Survival

CHEMOTHERAPY RECEIVED

ctDNA guided = 15%

Standard Management = 28%



Tie et al. J Clin Oncol 40, 2022 (suppl 17; abstr LBA100)



ctDNA can be considered in low-risk stage II colon cancer

If ctDNA is positive, who would not offer adjuvant chemotherapy?




Prevent and conquer cancer. Together.

What Are the Potential Applications of ctDNA? Minimal Residual Disease Stage III Colon Cancer

Adjuvant Therapy in Stage III CC: Room for Improvement


CURRENT (TNM):



FUTURE (ctDNA):


Sargent DJ et al. J Clin Oncol. 2009;27(12):1948-1955; André T et al. J Clin Oncol. 2015;33(35):4176-4187.

BESPOKE CRC: A Prospective, Case-Controlled Observational Study




NCT04264702 Kasi PM et al. *BMJ Open* 2021;11:e047831.


ctDNA-positivity at MRD time point is predictive of inferior DFS



ctDNA-based MRD testing is predictive of the benefit of ACT




Adjuvant strategy	ACT	Observation
Numbers of events (%)	96/177 (54.24)	29/35 (82.86)
2-year DFS post surgery, % (95% CI)	<mark>40.3</mark> (33.3 - 48.9)	<mark>24.7</mark> (13.2 - 46.3)
Median DFS post surgery, months (95%)	<mark>17.7</mark> (14.6 - 21.4)	<mark>7.1</mark> (4.6 - 21.4)




Adjuvant strategy	АСТ	Observation
Numbers of events (%)	43/506 (8.50)	37/408 (9.07)
2-year DFS post surgery, % (95% CI)	<mark>89.7</mark> (86.7- 92.9)	<mark>89.5</mark> (86.2- 92.9)
Median DFS post surgery, months (95%)	Not reached	Not reached

Shah P et al. 2025 ASCO GI; Abstract 15


Sustained ctDNA clearance is associated with superior DFS when compared to transient or no clearance



85% of patients with transient clearance develop molecular recurrence by the 15th month




Phase III CALGB/SWOG 80702 Study Design




Nowak JA et al. Gastrointestinal Cancers Symposium 2025; Abstract LBA14.



Phase III CALGB/SWOG 80702: Survival by ctDNA Status




Nowak JA et al. Gastrointestinal Cancers Symposium 2025; Abstract LBA14.






Phase III CALGB/SWOG 80702: Survival by ctDNA Status and Celecoxib Use



Nowak JA et al. Gastrointestinal Cancers Symposium 2025; Abstract LBA14.

Overall survival





Phase III CALGB/SWOG 80702: Summary and Conclusions

Endpoint	Comparison	Events / Total	Adjusted HR (95% CI)	Adjusted P-value	Adjusted Interaction P-value
Disease-free		247/930			0.4826
survival	ctDNA+: Celecoxib v Placebo (ref)		0.63 (0.43-0.92)	0.0167	
	ctDNA-: Celecoxib v Placebo (ref)		0.76 (0.53-1.08)	0.1262	
Overall survival		160/930			0.3873
	ctDNA+: Celecoxib v Placebo (ref)		0.63 (0.40-0.98)	0.0419	
	ctDNA-: Celecoxib v Placebo (ref)		0.84 (0.53-1.34)	0.4593	

Adjusted for ctDNA, age, sex, low dose aspirin usage, performance status, T stage, N stage, sidedness, days from surgery to blood draw, *KRAS*, *BRAF*, and MSI status

- In a subset of patients enrolled in CALGB/SWOG 80702, ctDNA status after surgery and prior to starting adjuvant therapy was highly prognostic of DFS and OS
- ctDNA status also appeared predictive of benefit of adjuvant celecoxib
- · Sensitivity and subgroup analyses are ongoing
- Studies on the predictive value of ctDNA for 3 versus 6 months of adjuvant FOLFOX are underway




Nowak JA et al. Gastrointestinal Cancers Symposium 2025; Abstract LBA14.

Take Home Points: What have these studies taught us?

- ctDNA is easily the most prognostic test we have ever seen in colon cancer
- Stage II Colon Cancer:
 - ctDNA may be ready for primetime for low-risk stage II colon cancer
 - If ctDNA is positive, who would not offer adjuvant chemotherapy?
- Stage III Colon Cancer:
 - Ongoing studies are critically needed to determine if ctDNA can be used to guide the management of patients with stage III colon cancer



CIRCULATE North America: Stage III Colon Cancer Study Amended Schema



- Study population amended to include <u>all</u> patients with Stage IIB, IIC, and Stage III colon adenocarcinoma
- One dose of chemotherapy allowed while awaiting Step 2 randomization




Pls: Dasari and Lieu (NRG-GI008 – NCT0517416)

Immune checkpoint inhibitors for patients with non-metastatic CRC



Dostarlimab for MSI-H Stage II-III Rectal Cancer




- Primary endpoints
 - Overall response rate at 6 months per MSKCC regression criteria
 - pCR or cCR rate at 12 months

• Secondary endpoint

• Safety and tolerability



Cercek A, et al. N Engl J Med 2022.



Take Home Points:

Neoadjuvant immune checkpoint inhibition appears <u>ready for</u> <u>primetime for rectal dMMR/MSI-H</u>


QUESTIONS:

What about stage I rectal cancer?

Should we be using nivo and ipi?

Does pCR mean cure?


What is the impact on pMMR/MSS patients?






NCCN Rectal Cancer Guidelines. Version 5.2024 – January 17, 2025

<u>AZUR-1</u>: Dostarlimab in dMMR/MSI-H Locally-Advanced Rectal Cancer



NCT05723562

NICHE-2 Study: Nivo/Ipi dMMR colon cancer






Chalabi et al. ESMO 2022; Abstract LBA7.

Prevent and conquer cancer. **Together**.


Results – 3-year disease-free survival 100%



Data cut-off: 11 September 2024

Take Home Points:

Neoadjuvant immune checkpoint inhibition should be considered for high-risk disease (T4b) colon cancer




QUESTIONS:

- Should we consider non-operative management for MSI-H/dMMR colon cancer?
- Are serial colonoscopies better or worse than a hemicolectomy?
- What is the best duration of immunotherapy prior to resection?
- What about adjuvant therapy?




AZUR-2: An Ongoing Phase III Study of Perioperative Dostarlimab for Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer



RESEARCH TO PRACTICE

www.clinicaltrials.gov. Accessed January 2024.

Adjuvant PD-L1 for Stage III colon cancer: ATOMIC Study (A021502)



NCT02912559

Discussion Questions

- A patient presents with Stage II colorectal cancer (CRC) with high-risk features and undergoes R0 resection. Regulatory and reimbursement issues aside, what would be your preferred approach to adjuvant therapy?
- A patient presents with Stage IIA CRC with no high-risk features and undergoes R0 resection. A ctDNA assay ordered after surgery is negative, but repeat testing at 3 months is positive. What would you most likely recommend?

Discussion Questions

- In which situations, if any, would you recommend celecoxib to a patient with Stage II or III colon cancer?
- Regulatory and reimbursement issues aside, what would you most likely recommend as neoadjuvant therapy for a patient with dMMR locally advanced rectal cancer?

Module 10: Colorectal Cancer

Optimizing the Care of Patients with Nonmetastatic Colorectal Cancer (CRC) — Dr Lieu

Recent Advances in the Management of Metastatic CRC — Dr Raghav



Recent Advances in the Management of Metastatic CRC (mCRC)


Kanwal Raghav, MD

Associate Professor, Dept. Gastrointestinal Medical Oncology Associate Vice President (AVP), Ambulatory Medical Operations The University of Texas MD Anderson Cancer Center, Houston, TX

Disclosures

Advisory Committees and	AbbVie Inc, AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc,
Contracted Research	Eisai Inc, Guardant Health, Janssen Biotech Inc, Merck, Pfizer Inc
Data and Safety Monitoring Boards/Committees	AbbVie Inc, Pfizer Inc


Phase III KEYNOTE-177 Study: Long Term Results Front-line Pembrolizumab versus chemotherapy for newly diagnosed MSI-H/dMMR mCRC




Pembrolizumab improved PFS over chemotherapy as first-line therapy for MSI-H/dMMR mCRC.


Andre et. al. NEJM 2020

imary Analysis




- First-line treatment with pembrolizumab versus chemotherapy did not result in a significant difference in survival of patients with MSI-H/d-MMR mCRC.
- 36% of patients in chemotherapy group met crossover criteria and received pembrolizumab + 24% of patients received off-study anti-PD-1/ PD-L1 therapies + 4% initially assigned to receive SOC refused treatment and had anti-PD1 off study.
- > PFS benefit of pembrolizumab was maintained.
- Grade 3/4 TRAEs occurred in 56% versus 78% of patients receiving Pembrolizumab versus SOC, respectively.






- First-line treatment with pembrolizumab versus chemotherapy results in a significant improvement of PFS and OS in survival of patients with MSI-H/d-MMR mCRC.
- ▶ 86% versus 34% of patients on pembrolizumab and chemotherapy arms, experienced a DOR of ≥ 24 months.
- Grade 3/4 TRAEs occurred in 22% versus 67% of patients receiving Pembrolizumab versus SOC, respectively.

Phase III CheckMate 8HW Trial: Key Results Nivolumab/Ipilimumab versus chemotherapy for patients with previously untreated MSI-H/dMMR mCRC




Front-line pembrolizumab improved PFS over SOC chemotherapy in MSI-H/dMMR mCRC.

First-Line Nivolumab Plus Low-Dose Ipilimumab for Microsatellite Instability-High/ Mismatch Repair-Deficient Metastatic Colorectal Cancer: The Phase II CheckMate 142 Study




First-line dual immune-checkpoint inhibition showed prolonged and robust survival outcomes in MSI-H/dMMR mCRC.




Andre et. al. NEJM 2024; Andre et. al. ASCO Gastrointestinal Cancers Symposium 2025

	Nivo + Ipi (296)	Nivo (286)		100-0	1 ;
	Efficacy		tients	80- 70-	A A A A A A A A A A A A A A A A A A A
cORR (95%CI)	71% (65-76)	58% (52-64)	Percentage of Patients	60- 50-	y age
CR	30%	28%	ercentag	40- 30-	à
PR	40%	30%	4	20- 10-	
PD	10%	19%		0	3 6 9
Median TTR	2.8 months	2.8 months		100-🝂 90-	
	Safety		atients	80- 70-	a a a a a a a a a a a a a a a a a a a
Grade ≥ TRAEs	22%	14%	Percentage of Patients	60- 50- 40-	Barra
Serious TRAEs	16%	7%	Percent	40- 30- 20-	
TRAEs with discontinuation	9%	4%		10- 0- 0	3 6 9




- PFS was longer with nivolumab plus ipilimumab versus nivolumab among patients with centrally confirmed MSI-H/dMMR mCRC.
- PFS was longer with upfront nivolumab plus ipilimumab than with chemotherapy among patients with MSI-H or dMMR mCRC.

Phase III BREAKWATER Trial: Primary Results Encorafenib/Cetuximab with chemotherapy versus SOC chemotherapy for untreated BRAF V600E-mutant mCRC



BRAFV600 mutant mCRC is associated with poor prognosis with conventional therapies.




Second-line dual BRAF-EGFR inhibition improves survival in BRAFV600 mutant mCRC.

Subgroup	Doublets + Bev No. Events of Total (%)	FOLFOXIRI + Bev No. Events of Total (%)	HR (95% CI)		Р
RAS and BRAF status					.337
RAS-BRAF wt	107 of 172 (62.2)	99 of 177 (55.9)	0.83 (0.63 to 1.10)		
<i>RAS</i> mut	316 of 430 (73.5)	289 of 422 (68.5)	0.82 (0.70 to 0.97)	· ⊢ - ·	
BRAF mut	43 of 54 (79.6)	53 of 61 (86.9)	1.11 (0.75 to 1.73)	Ĩ <u></u>	


> Intensification of systemic cytotoxic therapy does not improve survival in BRAFV600 mutant mCRC.

BREAKWAT



	EC+mFOLFOX6 (n=110)	SOC (n=110)		EC+mFOLFOX6 (n=110)	SOC (n=110)
Confirmed best overall response, n	(%)			74 (57 507)	70/54 400
Complete response	3 (2.7)	2 (1.8)	 Median time to response (range), weeks 	7.1 (5.7–53.7)	7.3 (5.4–48.0)
Partial response	64 (58.2)	42 (38.2)	 Estimated median duration of 	13.9 (8.5-NE)	11.1 (6.7–12.7)
Stable disease	31 (28.2)	34 (30.9)	response (range), months		
Confirmed objective response rate (95% Cl), % ^a	60.9 (51.6–69.5)	40.0 (31.3–49.3)	Patients with a duration of response of ≥ 6 months, <i>n</i> (%)	46 (68.7)	15 (34.1)
Odds ratio (95% Cl; 99.8% Cl) ^b	2.443 (1.403–4.253;	1.019–5.855)	Patients with a duration of response	15 (22.4)	5 (11.4)
One-sided P value	0.0008		of≥12 months <i>, n</i> (%)		**************************************

Addition of BRAF-targeted therapy to chemotherapy in front-line setting improved response rates and duration of response for BRAFV600 mutant mCRC.




- BRAF-targeted therapy + chemotherapy improved survival in front-line treatment of BRAFV600 mutant mCRC, compared to SOC.
- > 22% and 34% (21%-BRAF) patients received subsequent therapies.
- Grade 3/4 TRAEs occurred in 70% versus 54% of patients receiving EC+mFOLFOX6 versus SOC, respectively.

Table 3 | Most common all-causality treatment-emergent adverse events (≥10% of patients in any arm) by preferred term

	EC+mFOLFOX6 (n=231)		SOC (n=228)	
	Any grade	Grade≥3	Any grade	Grade≥3
Any adverse event	230 (99.6)	181 (78.4)	223 (97.8)	149 (65.4)
Nausea	118 (51.1)	6 (2.6)	110 (48.2)	7 (3.1)
Anemia	84 (36.4)	25 (10.8)	52 (22.8)	8 (3.5)
Diarrhea	79 (34.2)	3 (1.3)	107 (46.9)	8 (3.5)
Neutrophil count decreased	74 (32.0)	42 (18.2)	64 (28.1)	38 (16.7)
Decreased appetite	77 (33.3)	5 (2.2)	57 (25.0)	3 (1.3)
Vomiting	77 (33.3)	8 (3.5)	48 (21.1)	5 (2.2)
Asthenia	62 (26.8)	10 (4.3)	33 (14.5)	3 (1.3)
Pyrexia	60 (26.0)	4 (1.7)	31 (13.6)	1 (0.4)
Peripheral sensory neuropathy	57 (24.7)	13 (5.6)	49 (21.5)	5 (2.2)
Rash	57 (24.7)	2 (0.9)	6 (2.6)	0
Fatigue	56 (24.2)	6 (2.6)	57 (25.0)	6 (2.6)
Neuropathy peripheral	54 (23.4)	16 (6.9)	48 (21.1)	6 (2.6)
Arthralgia	51 (22.1)	2 (0.9)	8 (3.5)	0
Neutropenia	51 (22.1)	34 (14.7)	51 (22.4)	21 (9.2)
Alopecia	49 (21.2)	0	23 (10.1)	0
Constipation	47 (20.3)	1 (0.4)	44 (19.3)	1 (0.4)
Platelet count decreased	46 (19.9)	3 (1.3)	28 (12.3)	4 (1.8)
White blood cell count decreased	42 (18.2)	13 (5.6)	32 (14.0)	8 (3.5)
Lipase increased	46 (19.9)	34 (14.7)	22 (9.6)	12 (5.3)
Weight decreased	40 (17.3)	2 (0.9)	19 (8.3)	0
Skin hyperpigmentation	39 (16.9)	0	5 (2.2)	0
Abdominal pain	38 (16.5)	7 (3.0)	47 (20.6)	3 (1.3)
Dermatitis acneiform	35 (15.2)	2 (0.9)	1(0.4)	0
Hypokalemia	30 (13.0)	4 (1.7)	22 (9.6)	7 (3.1)
Aspartate aminotransferase increased	29 (12.6)	2 (0.9)	25 (11.0)	3 (1.3)

Anti-HER2 Therapy: Key Findings Trastuzumab plus Tucatinib/Pertuzumab and Trastuzumab Deruxtecan for previously treated HER2-positive mCRC



Strickler et. al. Lancet Oncology 2023; Strickler ASCO 2024

1(6.7)

Confirmed Objective Response Rate (%)

0

Frastuzumab + Tucatinib

Not available, n (%)


DESTINY-CRC02 Eligibility Criteria (N = 120)

- Confirmed metastatic colorectal adenocarcinoma
 HER2-positive per central IHC/ISH testing
 RAS-WT or RAS-MUT
- Progression after receiving >2 lines of therapy


	Trastuzumab deruxtecan 5·4 mg/kg group (n=82)	Trastuzumab deruxtecan 6·4 mg/kg group (n=40)
Confirmed objective response rate* (% [95% CI)	31 (37.8% [27.3-49.2])	11 (27.5% [14.6-43.9])
Complete response	0	0
Partial response	31 (38%)	11 (28%)
Stable disease	40 (49%)	23 (58%)
Progressive disease	8 (10%)	4 (10%)
Not evaluable	3 (4%)	2 (5%)
Confirmed disease control rate* (% [95% CI])	71 (86.6% [77.3-93.1])	34 (85.0% [70.2–94.3])
Confirmed clinical benefit rate* (% [95% CI])	37 (45·1% [34·1-56·5])	13 (32.5% [18.6–49.1])
Median duration of response*, months (95% CI)	5.5 (4.2-8.1)	5·5 (3·7–NE)
Median progression-free survival*, months (95% CI)	5.8 (4.6–7.0)	5.5 (4.2-7.0)
Patients with events	54 (66%)	27 (68%)
Median overall survival, months (95% CI)	13.4 (12.5–16.8)	NE (9·9–NE)
Patients with events	26 (32%)	13 (33%)
Median follow-up, months (IQR)	8.9 (6.7–10.5)	10.3 (5.9–12.7)
Median treatment duration†, months (IQR)	5.5 (3.6-8.4)	4·9 (2·8–8·5)
Median total dose†, mg/kg (IQR)	37.8 (26.9–59.4)	40.8 (25.4–66.1)
Median cycles initiated† (IQR)	7.0 (5.0–11.0)	7.0 (4.0–11.0)

Data are n (%) except where otherwise stated. NE=not estimable. *Assessed by blinded independent central review. †Based on the total population treated with trastuzumab deruxtecan; 5.4 mg/kg, n=83; 6.4 mg/kg, n=39 (safety analysis set).

Table 2: Antitumour activity endpoints




Raghav et. al. Lancet Oncology 2024



[>]ertuzumab **Frastuzumab**


Raghav et.al. JCO 2025

Anti-KRAS G12C Therapy: Emerging Data Sotorasib plus Panitumumab and Adagrasib plus Cetuximab for previously treated KRAS G12C-mutated mCRC




Isermann et. al. Trends in Cancer 2025; Liu et. al. Cancer Gene Therapy 2022; Sreter et. al. Frontiers in Oncology 2024

Rationale And Background



Variable	Adagrasib Monotherapy (N=43)†	Adagrasib plus Cetuximab (N = 28)‡
Objective response§		
Per blinded independent central review — no. of patients	10	13
% (95% CI)	23 (12-39)	46 (28–66)
As confirmed by investigator — no. of patients	8	13
% (95% CI)	19 (8-33)	46 (28–66)
Best overall response — no. (%)		
Complete response	0	0
Partial response	8 (19)	13 (46)
Stable disease	29 (67)	15 (54)
Progressive disease	6 (14)	0
Not evaluable	0	0
Median duration of response — mo	4.3	7.6
95% CI	2.3-8.3	5.7–NE
Median progression-free survival — mo¶	5.6	6.9
95% CI	4.1-8.3	5.4-8.1
Median overall survival — mo¶	19.8	13.4
95% CI	12.5-23.0	9.5-20.1




Adagrasib Monotherapy

Adagrasib + Cetuximab

Evaluable Patients

- Updated (N = 94) treated with Adagrasib + Cetuximab: ORR 34.0%; DCR 85.1%, mDOR 5.8 months, mPFS
 6.9 months and mOS 15.9 months.
- ➤ Grade 3/4 TRAEs occurred in 28% cases.




0.005

0.036


Fakih et.al. NEJM 2023

otorasib

Phase III FRESCO-2 Study: Fruquintinib for patients with mCRC who have progressed on or are intolerant to approved standard therapies



FRESCO: a randomized, double-blind, placebo-controlled, multicenter (28 hospitals in China), phase 3 clinical trial (December 2014 to May 2016)



	Fruquintinib, No.		Placebo, No.		Hazard Ratio	Favors Favors	Favors	P for
Group	Deaths	Total	Deaths	Total	(95% CI)	Fruquintinib	Placebo	Interactio
Age				20000000				
<65	151	228	88	110	0.56 (0.43-0.73)			.09
≥65	37	50	21	28	0.95 (0.55-1.63)			.09
Sex								
Men	108	158	77	97	0.52 (0.39-0.70)			0.5
Women	80	120	32	41	0.85 (0.57-1.29)	-		.06
Number of prior treatment lines o	on metastatic o	disease						
≤3	146	221	86	107	0.64 (0.49-0.83)			
>3	42	57	23	31	0.53 (0.31-0.90)			.87
Previous chemotherapy lines								
2 or 3	126	190	80	98	0.60 (0.46-0.80)			
>3	62	88	29	40	0.67 (0.43-1.05)	-		.50
Prior use of VEGF inhibitors								
Yes	60	84	35	41	0.68 (0.45-1.03)		-	.72
No	128	194	74	67	0.60 (0.45-0.80)	-8-		.12
Primary tumor site at the time of	diagnosisª							
Left side	141	214	91	115	0.56 (0.43-0.73)			.17
Right side	41	56	16	21	0.96 (0.53-1.75)			.17
Metastasis								
Single	5	13	2	4	1.03 (0.20-5.37)		•	.60
Multiple	183	265	107	134	0.61 (0.48-0.78)			.00
Liver metastasis								
Yes	134	185	85	102	0.59 (0.45-0.77)	-8-		
No	54	93	24	36	0.75 (0.46-1.21)		-	.43
Overall	188	278	109	138	0.62 (0.49-0.79)	-		
					0.1			5.0
					0.1	1. Hazard Ratio (S		5.0

Figure 3. Subgroup Analyses for Overall Survival (Primary Outcome) in Patients With Metastatic Colorectal Cancer Receiving Fruquintinib vs Placebo (Intent-to-Treat Population)


Li et. al. JAMA 2018

Fruquintinib Eligibility Criteria (N = 934) Confirmed metastatic ٠ (N = 461)FRESCO-2 colorectal adenocarcinoma Progressed on all SOC **Primary** • R Endpoint therapies including anti-2:1 VEGF and anti-EGFR OS therapy and TAS-102 Placebo and/or Regorafenib (N = 230)Median overall survival (months) Fruquintinib Placebo — Fruquintinib group: 7.4 (95% CI 6.7–8.2) group (n=461) group (n=230) — Placebo group: 4-8 (95% Cl 4-0-5-8) Region 42 (18%) 80. Stratified HR for death, North America 82 (18%) 0.66 (95% CI 0.55-0.80); p<0.0001 166 (72%) 329 (71%) Europe 40 (9%) 16 (7%) Japan 6 (3%) Australia 10 (2%) Overall survival (%) Fruquintinib improves survival 60 Number of previous treatment lines in metastatic disease Median 4 (3-6) over placebo in refractory mCRC. 4 (3-6) 125 (27%) 64 (28%) ≤3 336 (73%) 166 (72%) >3 40 **Previous therapies** 221 (96%) VEGF inhibitor 445 (97%) 88 (38%) EGFR inhibitor 180 (39%) Immune checkpoint inhibitor 11 (5%) 21 (5%) 20-BRAF inhibitor 9 (2%) 7 (3%) Previous trifluridine-tipiracil or regorafenib Trifluridine-tipiracil 240 (52%) 121 (53%) 18 (8%) Regorafenib 40 (9%) Both 181 (39%) 91 (40%) 8 10 11 12 13 17 18 0 0 14 15 16

Dasari et.al. The Lancet 2023

19

Endpoint Primary and esign $\check{\Box}$ Study



	Fruquintinib group (n=461)	Placebo group (n=230)	Treatment effect	Two-sided p value
Antitumour activity end	points			
Best overall response*				
Complete response	0	0		
Partial response	7 (2%)	0		
Stable disease	249 (54%)	37 (16%)		
Progressive disease	139 (30%)	143 (62%)	10731	
Not evaluable	6 (1%)	1 (<1%)	1974	
NA†	60 (13%)	49 (21%)		
Objective response rate	7 (2%, 0.6-3.1)	0 (0%, 0·0–1·6)	2% (0.4-2.7)	0.059
Disease control rate	256 (56%, 50.9-60.1)	37 (16%, 11.6-21.5)	39%‡ (32·8-46·0)	<0.0001
Duration of response, mor	nths			
Median	10·7 (3·9-NE)	0 (NA)	1.77.1	
Range	2.1-16.95	NA		

- Fruquintinib also improved PFS compared to placebo in a highly treatment refractory mCRC population, without any significant increase in ORR, but led to an increase in DCR.
- Grade 3/4 TRAEs occurred in 63% versus 50% of patients receiving Fruquintinib versus placebo, respectively.

	Fruquintinib	group (n=456)	Placebo gro	up (n=230)
	Any grade	Grade ≥3	Any grade	Grade ≥3
Adverse events of special interest				
Any	368 (81%)	169 (37%)§	122 (53%)	44 (19%)§
Hypertension	175 (38%)	64 (14%)	20 (9%)	2 (1%)
Dermatological toxicity	157 (34%)	31 (7%)	27 (12%)	1(<1%)
Thyroid dysfunction	123 (27%)	2 (<1%)	4 (2%)	0
Hepatic function abnormal	113 (25%)	38 (8%)	44 (19%)	21 (9%)
Infection	96 (21%)	30 (7%)	29 (13%)	13 (6%)
Proteinuria	80 (18%)	8 (2%)	12 (5%)	2 (1%)
Haemorrhage	65 (14%)	8 (2%)	22 (10%)	4 (2%)
Embolic and thrombotic events	21 (5%)	14 (3%)	5 (2%)	2 (1%)
Gastrointestinal perforation	16 (4%)	10 (2%)	1 (<1%)	1 (<1%)
Left ventricular ejection fraction decrease	5 (1%)	4 (1%)	6 (3%)	2 (1%)

Dasari et.al. The Lancet 2023

Discussion Question

 Regulatory and reimbursement issues aside, what is your most likely initial treatment recommendation for an asymptomatic, clinically stable 80-year-old patient with left-sided, pan-RAS wild-type, BRAF wild-type, HER2-negative, MSI-high mCRC?

Discussion Questions

 Regulatory and reimbursement issues aside, what would be your likely second-line treatment for a patient with RAS-mutant, MSS, HER2-positive mCRC who had experienced asymptomatic, low-volume disease progression on first-line FOLFOX/bevacizumab followed by maintenance bevacizumab? What about a patient with symptomatic, higher-volume disease?

Module 11: Urothelial Bladder Cancer

Management of Nonmetastatic Urothelial Bladder Cancer (UBC) — Dr Gupta

Optimizing the Treatment of Metastatic UBC — Dr Rosenberg

Module 11: Urothelial Bladder Cancer

Management of Nonmetastatic Urothelial Bladder Cancer (UBC) — Dr Gupta

Optimizing the Treatment of Metastatic UBC — Dr Rosenberg



Management of Nonmetastatic Urothelial Bladder Cancer (UBC)

Shilpa Gupta, M.D. Professor of Medicine Cleveland Clinic Lerner College of Medicine at CWRU Director, Genitourinary Oncology Program Cleveland Clinic Taussig Cancer Institute Cleveland, OH GMO'25 March 2, 2025




Unmet Needs in the Treatment of NMIBC and MIBC

- Only one-third of patients with NMIBC are given intravesical BCG
 - BCG shortages in the United States may affect access
- Close to half of patients with MIBC worldwide may not receive curative-intent therapy
- Patients who have undergone radical cystectomy for MIBC often have impaired HRQOL and a high risk of recurrence
- Development of effective, safe, and durable intravesical treatment remains a critical unmet clinical need for patients who want to avoid radical cystectomy
- Effective approaches post radical cystectomy are key to reducing the risk of recurrence

Tyson M et al. *J Clin Oncol.* 2019;37(suppl 15):e16012. 2. https://www.auanet.org/about-us/bcg-shortage-info. Westergren DO et al. *J Urol.* 2019;202:905-912. Choi H et al. *Transl Androl Urol.* 2020;9:2997-3006. Roupret M et al. *Eur Urol.* 2021;79:62-79.




Treatment Approaches for High-Risk NMIBC Unresponsive to BCG



Balar AV et al. Lancet Oncol. 2021;22:919-930., Vilaseca A et al. AUA 2024, Tyson MD et al. AUA 2024.,Li R et al. J Clin Oncol. 2022, Daneshmand S et al. AUA 2023.. Necchi A et al. ESMO 2023. Jacob J et al. AUA 2024., Shore ND et al. J Clin Oncol. 2017; Boorjian SA et al. Lancet Oncol. 2021, Chamie K. NEJM Evidence. 2022, Kamat AM et al. J Clin Oncol. 2023, McElree IM et al. J Urol. 2022



KEYNOTE-057 Cohort A: Pembrolizumab Monotherapy for BCG-Unresponsive, High-Risk NMIBC



Post Peenenee	Patients (N = 96)		
Best Response	n (%)	95% CI	
CR	39 (40.6)	30.7-51.1	
Non-CR	56 (58.3)	47.8-68.3	
Progression to T2	0	N/A	
NE	1 (1.0)	0-5.7	

Upstaging to ≥pT2 in 8.3% patients


Extended minimum follow-up of 26.3 mo

- Of 39 responders, 13 (33.3%) remained in CR ≥18 mo and 9 (23.1%) remained in CR ≥24 mo as of the data cutoff date
- No new safety risks were identified

Pembrolizumab was FDA approved for the treatment of patients with BCG-unresponsive, high-risk NMIBC with carcinoma in situ with or without papillary tumors who are ineligible for or have elected not to undergo cystectomy




Keynote-057 Longer Follow-up






KEYNOTE-057 Cohort B: Pembrolizumab for Papillary High-Risk NMIBC



Necchi A et al. Lancet Oncol. 2024;S1470-2045:00178-5.

Cleveland Clinic

CREST: Ongoing Phase III Trial of Sasanlimab Combined with BCG versus BCG Monotherapy for Patients with BCG-Naïve High-Risk NMIBC



Sasanlimab in Combination with BCG Improves Event-Free Survival in Patients with BCG-Naïve, High-Risk Non-Muscle Invasive Bladder Cancer Press Release: January 10, 2025

Positive topline results were announced from the pivotal Phase 3 CREST trial evaluating sasanlimab, an investigational anti-PD-1 monoclonal antibody (mAb), in combination with Bacillus Calmette-Guérin (BCG) as induction therapy with or without maintenance in patients with BCG-naïve, high-risk non-muscle invasive bladder cancer. The study met its primary endpoint of event-free survival by investigator assessment, demonstrating a clinically meaningful and statistically significant improvement with sasanlimab in combination with BCG (induction and maintenance) as compared to BCG alone (induction and maintenance).

The overall safety profile of sasanlimab in combination with BCG was generally consistent with the known profile of BCG and data reported from clinical trials with sasanlimab. The profile of sasanlimab was also generally consistent with the reported safety profile of PD-1 inhibitors.

Results will be submitted for presentation at an upcoming medical congress.



Key Ongoing Phase III Trials of antimPD-1/PD-L1 antibodies for BCG-naive NMIBC

Protocol	n	Randomization
ALBAN (NCT03799835)	517	Atezolizumab + BCGBCG
POTOMAC (NCT03528694)	1,018	 Durvalumab + BCG BCG
KEYNOTE-676 (NCT03711032)	1,397	 Pembrolizumab + BCG BCG

BCG = Bacillus Calmette-Guérin

www.clinicaltrials.gov; Accessed March 2025.



TAR-200: A Novel Drug Delivery System for Sustained Local Release of Gemcitabine in the Bladder




Grimberg DC, et al. *Eur Urol Focus* 2020;6:620-2; Daneshmand S, et al. *Urol Oncol* 2022;40:344.e1-344.e9; Tyson MD, et al. *J Urol* 2023:209:890-900.



Courtesy of Sia Daneshmand, MD

SunRISe-1: TAR-200 in BCG-Unresponsive High-Risk NMIBC



- Response is determined by quarterly cystoscopy, quarterly central cytology, and central pathology at weeks 24 and 48 and as clinically indicated
- The study protocol did not allow retreatment for nonresponders consistent with US FDA gudance




SunRISe-1: TAR-200 Monotherapy in BCG-Unresponsive, HR NMIBC (Cohort 2)

48)


Ш

Patients With CR (N



Landmark Time	DOR % (95% CI)		
6 months	93% (61-99)		
12 months	84% (49-96)		

- TAR-200 was well tolerated; mainly low–grade 1 or 2 AEs
- TAR-200–related SAEs, grade ≥3 AEs, and discontinuations were infrequent





Cleveland Clinic Daneshmand S et al. AUA 2023, Necchi A et al. ESMO 2023, 4. Jacob J et al. AUA 2024.

New Drug Application initiated with U.S. FDA for TAR-200, the first and only intravesical drug releasing system for patients with BCG-unresponsive high-risk non-muscle-invasive bladder cancer Press Release: January 15, 2025


The manufacturer announced it has initiated the submission of an original New Drug Application with the U.S. Food and Drug Administration (FDA) for TAR-200 for the treatment of patients with Bacillus Calmette-Guérin (BCG)-unresponsive high-risk non-muscle-invasive bladder cancer (HR-NMIBC) with carcinoma in situ (CIS), with or without papillary tumors.

The submission of this innovative intravesical drug releasing system is supported by data from the Phase 2b SunRISe-1 registration study. Data collected through the second quarter of 2024 and presented at the European Society for Medical Oncology (ESMO) 2024 Congress as a late-breaking oral presentation showed an 83.5 percent complete response (CR) rate and highly durable CRs without the need for reinduction – at a median follow-up of nine months, 82 percent of responders maintained response. At data cutoff in May 2024, safety and tolerability data presented at ESMO demonstrated a low occurrence of Grade 3 or higher treatment-related adverse events (TRAEs) (9 percent); five patients had TRAEs leading to discontinuation (6 percent) and no treatment-related deaths were reported.

https://www.jnj.com/media-center/press-releases/new-drug-application-initiated-with-u-s-fda-for-tar-200-the-first-and-onlyintravesical-drug-releasing-system-for-patients-with-bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer




Phase 3 SunRISe-3: BCG-Naïve, High-Risk NMIBC



- Primary endpoint: EFS (time from randomization to first occurrence of HR disease, progression,^b or any-cause death, whichever occurs first^c)
- Secondary endpoints: Overall CR rate (CIS only)^d/duration of CR,^e RFS, TTP, OS, cancer-specific survival, safety and tolerability, patient-reported outcomes



Phase 3 SunRISe-5: Recurrent, HR NMIBC After BCG



 Disease-free survival is defined as time from randomization to first recurrence of HR NMIBC (high grade Ta, any T1 or CIS), progression, or any cause death, whichever occurs first


The study will evaluate whether TAR-200 will prolong disease-free survival when compared with intravesical chemotherapy in patients with papillary-only HR NMIBC recurrent after BCG therapy who refuse or are unfit for RC

Key Efficacy and Safety Outcomes of Novel Therapies for the Treatment of HR NMIBC

Trial	BOND-003 ¹	CORE-001 ²	SunRISe-1 ³	QUILT 3.0324	NCT02773849 ⁵	Keynote-057 ^{6,7}	SWOG \$16058
Intervention	Cretostimogene	Cretostimogene + pembrolizumab	TAR-200	N-803+BCG	Nadofaragene	Pembrolizumab	Atezolizumab
Mechanism	Oncolytic immunotherapy	Oncolytic immunotherapy + checkpoint inhibitor	Chemotherapy	IL-15 superagonist + BCG	Gene therapy secreting IFN	Checkpoint inhibitor	Checkpoint inhibitor
Delivery	Intravesical	Intravesical + intravenous	Intravesical	Intravesical	Intravesical	Intravenous	Intravenous
Stage	Phase 3 (enrollment completed)	Phase 2 ongoing	Phase 2 (enrollment completed)	FDA approved April 22, 2024	FDA approved	FDA approved (CIS)	Phase 2 (enrollment completed)
Sample size	N = 112	N = 35	N = 85 (48)	N = 77	N = 98	N = 96 (A) N = 132 (B)	N = 129
DOR ≥12m or 12-m K-M DOR estimates	83%	88%	74.6%	58%	46%	19% (A) 43.5% (B)	56%
Safety	0% grade 3-4 TRAE	4 pt pembro- related discontinuation	8.2% TRAE	16% SAE 7% discontinuation	4% grade 3-4 TRAE; 3% discontinuation	A: 11% grade 3 TRAE; 2% grade 4 TRAE; 11% discontinuation	16% grade 3-5 TRAE



FGFR Mutations Are Frequently Observed in Bladder Cancer



FGFR inhibitors can be effective across the disease spectrum

Knowles MA et al. Nat Rev Cancer. 2015;15:25-41.

Cleveland Clinic

TAR-210 Erdafitinib Intravesical Delivery First-in-Human Phase 1 Trial

Molecular Eligibility

FGFR alterations:

- Flexible molecular eligibility strategy
 used
 - Local or central fresh/ archival tissue-based testing by NGS or PCR

or


Central urine cell-free DNA
 NGS testing

HR NMIBC (Cohort 1)

- Recurrent, high-grade Ta/T1, papillary only, no CIS
- BCG-experienced/unresponsive and not undergoing radical cystectomy
- TURBT with complete resection of all visible disease prior to treatment

IR NMIBC (Cohort 3)

- Recurrent, history of low-grade only Ta/T1 disease
- Visible target lesions prior to treatment (chemoablation design)




Response assessed every 3 months with continued treatment for up to 1 year if recurrence free (cohort 1) or complete response (cohort 3)

Liu S, Yuan Y. *J R Stat Soc Ser C Appl Stat.* 2015;64:507-523, Yuan Y et al. *Clin Cancer Res.* 2016;22:4291-4301. Vilaseca A et al. AUA 2024. Abstract PD48-02.




TAR-210 HR NMIBC (Cohort 1): Response Rate



- 90% estimated 12-month RFS rate^a (n = 21)
 - Median RFS was not estimable
 - 2 of 21 patients have recurred
 - Median duration of follow-up 8.9 months
- No difference observed in RFS between the TAR-210 dose levels



TAR-210 IR NMIBC (Cohort 3): Response Rate



6 months

9 months

100 (100-100)

89 (43-98)

Phase 3 MoonRISe-1 Underway²: TAR-210 vs IV chemotherapy in IR NMIBC with susceptible *FGFR* alterations



Phase III MoonRISe-1: Study Design

Key eligibility criteria

- Adults (aged ≥18 years)
- Histologically confirmed IR NMIBC:
 - Ta LG/grade 1
 - Recurrent or
 - Primary: Multifocal, or ≥3 cm
 - -or-
 - Ta LG/grade 2
 - Primary
 - Recurrent
- With ≥1 risk factor^a
- FGFR2/3 alterations by central or local tissue or urine testing

Stratification factors


- Anticipated choice of intravesical chemotherapy
- Newly diagnosed versus recurrent disease
- Cystoscopic assessment method (white light vs photodynamic diagnostics)
- **Primary end point** Disease-free survivalb **TAR-210** (n≈270) (Q12W for 1 year) 1:1 (N≈540) Key secondary end points R Time to next treatment Investigator's choice of intravesical High grade recurrence-free survival chemotherapy (n≈270) MMC or gemcitabine Rate of diagnostic and therapeutic (QW for 4 to 6 doses [induction] urological interventions and maintenance for 6 months to 1 year) Safety and tolerability

NCT06319820

- All visible papillary disease must be fully resected prior to randomization
- Assessments of recurrence or progression include urine cytology, cystoscopy, for cause TURBT or biopsy of bladder lesions, ultrasound, and urography
- The follow-up phase for patients meeting the primary endpoint is up to ≈ 5 years




MIBC has a huge societal burden





Neoadjuvant cisplatin-based chemotherapy (NAC) prior to RC improves survival in cisplatin-eligible MIBC patients



Meta-analyses show an absolute 5-year OS improvement of 8% with NAC

dd-MVAC and GC are both standard options

High risk of recurrence despite NAC and surgery


50% patients deemed ineligible for NAC, 30% refuse NAC

Lack of neoadjuvant treatment options for cisplatin-ineligible MIBC patients

ABC metaanalayis collaboration Vale CL eta I. European urology 2005, Yin M et al. Oncologist 2016, Galsky MD Cancer 2015, Flaig T el al. CCR 2021



Adjuvant therapy ultimate goal: Improve DFS, OS



EORTC 30994: Immediate versus deferred chemotherapy (Investigator's choice MVAC, dd-MVAC,GC) after RC in patients with pT3–pT4 or N+ M0 Bladder Cancer

Sternberg CN et al, Lancet Oncol. 2015, ABC Metaanalysis European Urology 2022,



ASCO[°] Genitourinary Cancers Symposium




PRESENTED BY: Shilpa Gupta, MD 🔰@shilpaono

Presentation is property of the author and ASCO. Permission required for reuse; contact permissions@asco.org


Completed Adjuvant IO trials in high-risk MIUC


High risk MIUC: if received NAC- ypT2-T4a/ypN+ or pT3-T4a/pN+ if not eligible for or declined adjuvant cisplatin-based chemotherapy





IMvigor 010: No DFS or OS improvement with atezolizumab





Data cutoff: November 30, 2019. Median follow-up: 21.9 mo. Most common subsequent non-protocol therapies included immunotherapy (9% in atezolizumab arm vs 21% in observation arm) chemotherapy (27% vs 25%) and targeted therapy (5% vs 2%). * OS results are shown for descriptive purposes only. HR stratified by tumor stage, nodal status and PD-L1 status.

Bellmunt J et al. Lancet 2021








ркезентер ву: Shilpa Gupta, MD 🔰 @shilpaonc

CheckMate 274: 3 year DFS and 1st OS data




Galsky MD et al. JCO 2024



AMBASSADOR: DFS Benefit with Pembrolizumab

DFS (ITT Population)


Overall Survival



Apolo AB et al. NEJM 2024




AMBASSADOR: Patients with PD-L1+ tumors did worse



CI, confidence interval; CPS, combined positive score; DFS, disease-free survival; HR, hazard ratio; NR, not reached.

Cleveland Clinic


Improved OS, DFS with atezolizumab in ctDNA+ patients in IMvigor010





Powles T et al. Nature 2021

ctDNA guided adjuvant IO trials



MODERN



Ongoing Phase 3 Peri-operative IO-based Trials in MIBC


	Clinical Trial	Ν	Treatment Arms	Eligibility
CISPLATIN ELIGIBLE	KEYNOTE-866	870	Pembro + GC vs GC	T2-4aN0M0
	KEYNOTE-B15/EV-304	784	Pembro +EV vs GC	T2-T4aN0M0 T1-T4aN1M0
	NIAGARA	1050	Durva+ GC vs GC	T2-4aN1M0
CISPLATIN- INELIGIBLE	ENERGIZE	1200	Nivo + GC vs GC	T2-4aN0M0
	KEYNOTE-905/ EV-303	836	RC vs Pembro+EV vs Pembro	T2-4aN0M0
	VOLGA	830	RC vs Druva/Tremi+EV vs Durva+EV	T2-4aN0M0

Primary Endpoints pCR, EFS Adjuvant IO in experimental arm NO adjuvant IO in control arm




NIAGARA: Study Design






*Evaluated by blinded independent central review or central pathology review (if a biopsy was required for a suspected new lesion).**Evaluated by blinded central pathology review. ClinicalTrials.gov, NCT03732677; EudraCT number, 2018-001811-59. CrCI, creatinine clearance; DFS, disease-free survival; DSS, disease-specific survival; EFS, event-free survival; HRQoL, health-related quality of life; IV, intravenous; MFS, metastasis-free survival; MIBC, muscle-invasive bladder cancer; OS, overall survival; pCR, pathologic complete response; PD-L1, programmed cell death ligand-1; Q3W, every 3 weeks; Q4W, every 4 weeks; R, randomised; RC, radical cystectomy; UC, urothelial carcinoma.




NIAGARA: Event-free Survival Sensitivity Analysis

BARCELONA CONGRESS



BARCELONA Congress

NIAGARA: Pathologic Complete Response (ITT)





Conclusions

- Treatments for NMIBC and MIBC are rapidly evolving and improvement in outcomes seen with immunotherapy and novel therapies
- Unmet need to identify valid biomarkers to select patients for the most appropriate treatment, spare unnecessary toxicity and allow bladder preservation



Discussion Questions

 What is your global perspective on the overall efficacy and tolerability of the TAR-200 delivery system? How would you compare the tolerability of TAR-200 to standard chemotherapy? In which settings would you like to utilize TAR-200 alone or with cetrelimab?

Discussion Questions

 What is your global perspective on the TAR-210 erdafitinib intravesical delivery system for patients with NMIBC and an FGFR alteration? How would you compare the tolerability of TAR-210 to standard erdafitinib administration? If this strategy were available, for which patients would you use it?

Module 11: Urothelial Bladder Cancer

Management of Nonmetastatic Urothelial Bladder Cancer (UBC) — Dr Gupta

Optimizing the Treatment of Metastatic UBC — Dr Rosenberg

Optimizing the Treatment of Patients with Metastatic Urothelial Cancer


Jonathan Rosenberg, MD

Chief, Genitourinary Oncology Service Enno Ercklentz Chair Department of Medicine Memorial Sloan Kettering Cancer Center Professor of Medicine Weill Cornell Medical College

Disclosures


Advisory Committees	Astellas, Seagen Inc, Tyra Biosciences Inc
Consulting Agreements	Aadi Bioscience, Aktis Oncology, Alligator Bioscience, Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, EMD Serono Inc, Genentech, a member of the Roche Group, Generate Biomedicines, Gilead Sciences Inc, Hengrui Therapeutics Inc, Imvax Inc, Janssen Biotech Inc, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Pfizer Inc, Samsung Bioepis, Seagen Inc, Tyra Biosciences Inc
Contracted Research	Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Seagen Inc


Avelumab Maintenance Therapy




- Best response to 1L chemotherapy (CR or PR vs SD)
- Metastatic site (visceral vs nonvisceral) when initiating 1L chemotherapy

Avelumab Maintenance Therapy – Survival Outcomes






CheckMate 901: two phase 3 trials of immune checkpoint blockade



CheckMate 901: Study design

Does Nivolumab improve outcomes when added to gemcitabine-cisplatin?




Median (range) study follow-up, 33.6 (7.4-62.4) months

Primary endpoints: OS, PFS per BICR **Key secondary endpoints:** OS and PFS by PD-L1 ≥ 1%,^d HRQoL **Key exploratory endpoints:** ORR per BICR, safety

Avelumab or pembrolizumab was subsequently administered before disease progression in 2.0% of the patients in the nivolumab-combination group and in 14.5% of those in the gemcitabine–cisplatin group.

Nivolumab improves progression-free and overall survival when added to gemcitabine and cisplatin chemotherapy



Treatment	Events/patients	Median OS (95% CI), months							
NIVO+GC	172/304	21.7 (18.6-26.4)							
GC	193/304	18.9 (14.7–22.4)							
HR (95% CI), 0.78 (0.63–0.96) P = 0.0171									

Treatment	Events/patients	Median PFS (95% CI), months							
NIVO+GC	211/304	7.9 (7.6-9.5)							
GC	191/304	7.6 (6.1–7.8)							
HR (95% CI), 0.72 (0.59–0.88) <i>P</i> = 0.0012									

© 2024 Memorial Sloan Kettering Cancer Center, et al. All rights reserved.

Adapted from M van der Heijden; ESMO LBA7 2023

CheckMate 901: Treatment-related AEs in all treated patients


	⊦GC (n = 304)	GC (n = 288)					
Any grade	Grade ≥ 3 ^b	Any grade	Grade ≥ 3 ^b				
97	62	93	52				
21	11	17	8				
57	22	18	48				
47	< 1	1	48				
	31 19	15	30				
	25 14	11 21					
	24 2	1 24					
	22 1	< 1 16					
	22 8	5 15					
	21 10	4 14					
	18 1	2 17					
	15 1	2 16					
	15 7	5 12					
	14 1	0 3					
	14 0	0 < 1 14	Grade 1-				
	13 1	<1 3					
	13 1	0 9	Grade ≥				
	13 0	0	Grade 2				
	13 < 1	0 12	_				
	13 2	2 11					
	1						
60 40			40 60				
	Any grade 97 21 57 47	Any grade Grade $\geq 3^b$ 97 62 21 11 57 22 47 21 31 19 25 14 24 2 22 1 22 8 21 10 18 1 15 7 14 1 13 1 13 1 13 1 13 1 13 1 13 2	Any grade Grade $\geq 3^{b}$ Any grade 97 62 93 21 11 17 57 22 18 47 <1				

Adapted from M van der Heijden; ESMO LBA7 2023

© 2024 Memorial Sloan Kettering Cancer Center, et al. All rights reserved.

Modest increase in grade \geq 3 toxicity

Enfortumab vedotin: Nectin-4 directed ADC



Targets Nectin-4 which is highly expressed in urothelial cancers

IgG1 monoclonal antibody with intact Fc receptor

Drug : antibody ratio ~3.8


Cleavable drug linker: maleimidocaproyl valine-citrullinep-aminobenzyloxycarbonyl

Improves OS in platinum- and immunotherapy-treated patients

Rosenberg, et al. J Clin Oncol. 2019; 37(29):2592-2600 Powles, et al. NEJM. 2021; 384:1125-1135

EV-301: EV improves survival compared to standard chemotherapy in platinum and ICB refractory patients

Overall Survival According to Treatment Group




PFS 5.55 vs. 3.71 months; HR 0.62; 95% Cl, 0.51 to 0.75; P<0.001

Powles, Rosenberg, et al. NEJM 2021

© 2024 Memorial Sloan Kettering Cancer Center, et al. All rights reserved.

EV-103 Cohort K: 1st-line EV +/- pembrolizumab



EV + Pembro (n = 69)

EV Monotherapy (n = 65)


EV/Pembro	activity	independent of PD-L1
status		

- 27/44 (61.4%) cORR in CPS<10
- 21/31 (67.7%) cORR in CPS≥10

O'Donnell et al. JCO 2023 41(25):4107-4117.

	EV+Pembro (N=76)	EV Monotherapy (N=73)
Confirmed ORR (95% CI)	64.5% (52.7-75.1)	45.2% (33.5-57.3)
Complete response	10.5%	4.1%
Partial response	53.9%	41.1%
Progressive disease	7.9%	9.6%
Not evaluable or no assessment	5.3%	10.9%
PFS	Not reached	8.0 months
Duration of response	Not reached	13.2 months

EV-302/KEYNOTE-A39 (NCT04223856)



Stratification factors: cisplatin eligibility (eligible/ineligible), PD-L1 expression (high/low), liver metastases (present/absent)

Cisplatin eligibility and assignment/dosing of cisplatin vs carboplatin were protocol-defined; patients received 3-week cycles of EV (1.25 mg/kg; IV) on Days 1 and 8 and P (200 mg; IV) on Day 1


Statistical plan for analysis: the first planned analysis was performed after approximately 526 PFS (final) and 356 OS events (interim); if OS was positive at interim, the OS interim analysis was considered final

Adapted from Powles et al. ESMO 2023 LBA6

© 2024 Memorial Sloan Kettering Cancer Center, et al. All rights reserved.

Trial amended to allow avelumab maintenance

EV-302: EV+P reduces risk of progression or death by 55% and death by 53%



	N	Events (%)	HRª (95% CI)	2-sided P value	mPFS (95% CI), months
EV+P	442	223 (50.5)	0.45	<0.00004	12.5 (10.4-16.6)
Chemotherapy	444	307 (69.1)	(0.38-0.54)	<0.00001	6.3 (6.2-6.5)


	N	Events (%)	HR ^a (95% CI)	2-sided P value	mOS (95% CI), months
EV+P	442	133 (30.1)	0.47		31.5 (25.4-NR)
Chemotherapy	444	226 (50.9)	(0.38-0.58)	<0.00001	16.1 (13.9-18.3)

© 2024 Memorial Sloan Kettering Cancer Center, et al. All rights reserved.

Adapted from Powles et al. ESMO 2023 LBA6

EV-302: Confirmed Overall Response per BICR

Significant improvement in objective response rate was observed with EV+P



	EV+P (N=437)	Chemotherapy (N=441)			
Confirmed ORR, n (%) (95% CI)	296 (67.7) (63.1-72.1)	196 (44.4) (39.7-49.2)			
2-sided P value	<0.00001				
Best overall response ^a , n (%)					
Complete response	127 (29.1)	55 (12.5)			
Partial response	169 (38.7)	141 (32.0)			
Stable disease	82 (18.8)	149 (33.8)			
Progressive disease	38 (8.7)	60 (13.6)			
Not evaluable/No assessment ^b	21 (4.8)	36 (8.2)			


EV+P ORR is remarkably consistent across studies

Adapted from Powles et al. ESMO 2023 LBA6

© 2024 Memorial Sloan Kettering Cancer Center, et al. All rights reserved.

EV-302: Treatment-related adverse events

Grade ≥3 events were 56% in EV+P and 70% in chemotherapy



Serious TRAEs:

- 122 (27.7%) EV+P
 - 85 (19.6%) chemotherapy

TRAEs leading to death (per investigator):

- EV+P: 4 (0.9%)
- Asthenia
- Diarrhea
- Immune-mediated lung
 disease
- Multiple organ dysfunction syndrome


Chemotherapy: 4 (0.9%)

- Febrile neutropenia
- Myocardial infarction
- Neutropenic sepsis
- Sepsis

Median number of cycles (range): 12.0 (1,46) for EV+P; 6.0 (1,6) for chemotherapy

Nectin-4 expression does not predict outcome compared to chemotherapy, though low levels may have a negative prognostic effect

OS Benefit with EV+P in Both <275 and ≥275 Nectin-4 H-Score Subgroups




Powles et al. Annals of Oncology (2024) 35 (suppl_2): S1135-S1169.

© 2024 Memorial Sloan Kettering Cancer Center, et al. All rights reserved.


Data cutoff: 8 August 2023. EV, enfortumab vedotin; P, pembrolizumab. ^aThe median Nectin-4 H-score was 275 across patients in both arms.

Duration of response and progression free survival in EV-103 Cohort A/DE at median follow-up of 5 years Responses durable after 2 years



	Ν	Events	Median (months)	95% CI
DOR	33	15	22.1	(8.4, NR)
PFS	45	25	12.7	(6.1, NR)


In this cisplatin-ineligible cohort, K-M estimate of 41.9% of patients were alive at 5 years follow-up



EV-302: median 2.5 years follow-up

OS in the Overall Population


Risk of death was reduced by almost 50%



Data cutoff: August 8, 2024.

EV, enfortumab vedotin; P, pembrolizumab; OS, overall survival. ^aEvents/N were 203/442 for EV+P and 297/444 for chemotherapy. ^bP-value is nominal and descriptive

Targeting FGFR3: Phase 3 THOR Study: 2 cohorts



Primary end point:OS


Key secondary end points:

- PFS
- ORR
- Safety

Loriot Y et al. N Engl J Med 2023; 389:1961-1971 Siefker-Radtke et al. Annals of Oncology 2024 (35): 107-117. NCT03390504

Erdafitinib in FGFR3 or FGFR2 mutated refractory mUC

Cohort 1: Erdafitinib improves survival compared to taxane or vinflunine in IOexperienced patients




No. at Risk

eu ualaj																	
136 117 97	74	46	35	25	17	15	9	5	3	3	2	2	2	1	0	No. at risk	Months Since Randomization
(0) (10) (20)) (25)	(35)	(39)	(44)	(47)	(48)	(52)	(55)	(56)	(56)	(57)	(57)	(57)	(58)	(59)	Erdəfitinib	175160131100 78 60 52 41 30 28 23 21 13 9 7 2 1 1 1 0
200 01 00		~ ~	~~		-	~	~	_	_		~	•	~	~	~		
(0) (17) (25)) (30)	(35)	(41)	(45)	(47)	(47)	(49)	(50)	(50)	(51)	(52)	(52)	(52)	(52)	(52)	Pembrolizumab	176148119103 84 72 60 52 43 34 29 23 19 11 8 8 1 1 0 0
	136 117 97 (0) (10) (20 130 87 66	136 117 97 74 (0) (10) (20) (25) 130 87 66 43	136 117 97 74 46 (0) (10) (20) (25) (35) 130 87 66 43 30	136 117 97 74 46 35 (0) (10) (20) (25) (35) (39) 130 87 66 43 30 18	136 117 97 74 46 35 25 (0) (10) (20) (25) (35) (39) (44) 130 87 66 43 30 18 13	136 117 97 74 46 35 25 17 (0) (10) (20) (25) (35) (39) (44) (47) 130 87 66 43 30 18 13 9	136 117 97 74 46 35 25 17 15 (0) (10) (20) (25) (35) (39) (44) (47) (48) 130 87 66 43 30 18 13 9 8	136 117 97 74 46 35 25 17 15 9 (0) (10) (20) (25) (35) (39) (44) (47) (48) (52) 130 87 66 43 30 18 13 9 8 3	136 117 97 74 46 35 25 17 15 9 5 (0) (10) (20) (25) (35) (39) (44) (47) (48) (52) (55) 130 87 66 43 30 18 13 9 8 3 2	136 117 97 74 46 35 25 17 15 9 5 3 (0) (10) (20) (25) (35) (39) (44) (47) (48) (52) (55) (56) 130 87 66 43 30 18 13 9 8 3 2 2	136 117 97 74 46 35 25 17 15 9 5 3 (0) (10) (20) (25) (35) (39) (44) (47) (48) (52) (55) (56) (56) 130 87 66 43 30 18 13 9 8 3 2 2 1	136 117 97 74 46 35 25 17 15 9 5 3 3 2 (0) (10) (20) (25) (35) (39) (44) (47) (48) (52) (55) (56) (57) 130 87 66 43 30 18 13 9 8 3 2 2 1 0	136 117 97 74 46 35 25 17 15 9 5 3 3 2 2 (0) (10) (20) (25) (35) (39) (44) (47) (48) (52) (55) (56) (57) (57) 130 87 66 43 30 18 13 9 8 3 2 2 1 0 0	136 117 97 74 46 35 25 17 15 9 5 3 3 2 2 2 (0) (10) (20) (25) (35) (39) (44) (47) (48) (52) (55) (56) (57) (57) (57) 130 87 66 43 30 18 13 9 8 3 2 2 1 0 0 0	136 117 97 74 46 35 25 17 15 9 5 3 3 2 2 2 1 (0) (10) (20) (25) (35) (39) (44) (47) (48) (52) (55) (56) (57) (57) (57) (58) 130 87 66 43 30 18 13 9 8 3 2 2 1 0 0 0 0	136 117 97 74 46 35 25 17 15 9 5 3 3 2 2 2 1 0 (0) (10) (20) (25) (35) (39) (44) (47) (48) (52) (55) (56) (57) (57) (57) (58) (59) 130 87 66 43 30 18 13 9 8 3 2 2 1 0 0 0 0 0	136 117 97 74 46 35 25 17 15 9 5 3 3 2 2 1 0 (0) (10) (20) (25) (35) (39) (44) (47) (48) (52) (55) (56) (57) (57) (58) (59) Frdafitinib

Loriot Y et al. N Engl J Med 2023; 389:1961-1971

Cohort 2: Erdafitinib does not improve survival compared to pembrolizumab in IOnaïve patients



Siefker-Radtke et al. Ann Oncol 2024 (35): 107-117.

Adverse events associated with erdafitinib treatment

Hyperphosphatemia is on-target effect and requires monitoring for dose up-titration at 14-21 days

Gastrointestinal toxicity is common, including **stomatitis**, **dry mouth, and dysgeusia**

Skin and nail toxicity are frequent

Grade 3 **central serous retinopathy** (in 2.2%) and other eye disorders (in 2.2%) were uncommon but require monitoring per package insert


Table 2. Adverse Events in the Safety Population.*											
Event		Erdafitinib	o (N=135)		Chemothera	Chemotherapy (N=112)					
	Any Grade	Grade 1	Grade 2	Grade ≥3	Any Grade	Grade 1	Grade 2	Grade ≥3			
				number	(percent)						
Hyperphosphatemia	108 (80.0)	70 (51.9)	31 (23.0)	7 (5.2)	0	0	0	0			
Diarrhea	84 (62.2)	49 (36.3)	31 (23.0)	4 (3.0)	19 (17.0)	7 (6.2)	9 (8.0)	3 (2.7)			
Stomatitis	65 (48.1)	22 (16.3)	32 (23.7)	11 (8.1)	14 (12.5)	4 (3.6)	8 (7.1)	2 (1.8)			
Dry mouth	53 (39.3)	45 (33.3)	8 (5.9)	0	4 (3.6)	4 (3.6)	0	0			
Palmar–plantar erythrodysesthesia syndrome	41 (30.4)	6 (4.4)	22 (16.3)	13 (9.6)	1 (0.9)	0	1 (0.9)	0			
Dysgeusia	37 (27.4)	28 (20.7)	8 (5.9)	1 (0.7)	8 (7.1)	5 (4.5)	3 (2.7)	0			
Alanine aminotransferase increased	37 (27.4)	24 (17.8)	9 (6.7)	4 (3.0)	4 (3.6)	2 (1.8)	1 (0.9)	1 (0.9)			
Constipation	36 (26.7)	24 (17.8)	12 (8.9)	0	31 (27.7)	13 (11.6)	16 (14.3)	2 (1.8)			
Decreased appetite	36 (26.7)	18 (13.3)	14 (10.4)	4 (3.0)	23 (20.5)	10 (8.9)	10 (8.9)	3 (2.7)			
Anemia	35 (25.9)	10 (7.4)	15 (11.1)	10 (7.4)	36 (32.1)	8 (7.1)	19 (17.0)	9 (8.0)			
Alopecia	34 (25.2)	29 (21.5)	4 (3.0)	1 (0.7)	27 (24.1)	16 (14.3)	11 (9.8)	0			
Dry skin	31 (23.0)	23 (17.0)	6 (4.4)	2 (1.5)	5 (4.5)	4 (3.6)	1 (0.9)	0			
Onycholysis	31 (23.0)	9 (6.7)	14 (10.4)	8 (5.9)	1 (0.9)	0	1 (0.9)	0			
Weight decreased	30 (22.2)	12 (8.9)	15 (11.1)	3 (2.2)	3 (2.7)	3 (2.7)	0	0			
Aspartate aminotransferase increased	29 (21.5)	21 (15.6)	5 (3.7)	3 (2.2)	3 (2.7)	2 (1.8)	1 (0.9)	0			
Onychomadesis	28 (20.7)	9 (6.7)	17 (12.6)	2 (1.5)	2 (1.8)	1 (0.9)	1 (0.9)	0			
Nail discoloration	24 (17.8)	16 (11.9)	7 (5.2)	1 (0.7)	2 (1.8)	1 (0.9)	1 (0.9)	0			
Dry eye	23 (17.0)	20 (14.8)	3 (2.2)	0	2 (1.8)	1 (0.9)	1 (0.9)	0			
Asthenia	20 (14.8)	6 (4.4)	12 (8.9)	2 (1.5)	28 (25.0)	9 (8.0)	15 (13.4)	4 (3.6)			
Nausea	20 (14.8)	10 (7.4)	8 (5.9)	2 (1.5)	27 (24.1)	15 (13.4)	10 (8.9)	2 (1.8)			
Neutropenia	0	0	0	0	22 (19.6)	1 (0.9)	5 (4.5)	16 (14.3)			
Fatigue	20 (14.8)	12 (8.9)	8 (5.9)	0	21 (18.8)	13 (11.6)	4 (3.6)	4 (3.6)			

© 2024 Memorial Sloan Kettering Cancer Center, et al. All rights reserved.

* Listed are adverse events (of any cause) that emerged or worsened during treatment, according to preferred term and highest grade, and that were reported in more than 15% of the patients in either treatment group.


FGFR3 selective FGFR inhibitors

LOXO-435: NCT05614739



· Responses were also observed in non mUC patients: intrahepatic cholangiocarcinoma and ovarian (Brenner) cancer (n=1 each)

Tyra300: NCT05544552




Confirmed ORR 41% at doses ≥200 mg BID

Iyer et al. J Clin Oncol 43, 2025 (suppl 5; abstr 662)

6/11 PR at doses ≥90mg daily

Zhang et al. European Journal of Cancer 211S1 (2024) 114563


Frequency of HER2 alterations is high in bladder cancer



Can co-exist with mutations in a subset of tumors


• Overexpression in about 25-40% of UC tumors

DESTINY-PanTumor02: Trastuzumab Deruxtecan (T-DXd) leads to high response rates in HER2+ urothelial cancer



ORR 39%


T-DXd outcomes by HER2 status in mUC



Novel ADCs against other targets in urothelial cancer

- Nectin-4 may still be a valid target after POD on EV
 - Radiopharmaceuticals
 - ADCs with other payloads (LY4101174, LY4052031, IPH4502)
- HER2-targeted ADC T-DXd already approved in UC
 - Disitamab vedotin has high activity
- While sacituzumab govitecan did not improve OS in TROPiCS-04, TROP2 remains a valid target for UC therapy
 - Sacituzumab tirumotecan (MK-2870)
 - Datopotamab deruxtecan

Bispecific antibody drug conjugate targeting EGFR and HER3




- Anti-EGFR antibody is derived from cetuximab high affinity antibody
- Two HER3 single-chain fragment variable (scFv) with lower affinity
- Anti-EGFR antibody is fused to anti-HER3 scFvs with a glycine-serine linker
- Tetrapeptide-based cathepsin cleavable linker
 - Cytotoxic is Ed-04, a camptothecin derivative inhibitor of topoisomerase 1
- Drug-to-antibody ratio of 8


Ma, et al. *Lancet Oncology* 2024; 25:901-911 Wan et al. Cancer Res 2023; 83(7_Suupl) Abstract 2642

mUC Patients treated at 2.2 mg/kg d1 and d8 q3 weeks

- Majority of patients had tumor reductions
- At 2.2mg/kg dose level, ORR 40.7%, and 75% in one prior line of therapy (n=12)
- Activity appears higher in 2nd line population, but limited sample size



All patients



2nd-line only

Discussion Questions

- Regulatory and reimbursement issues aside, in which line of therapy would you generally offer targeted treatment to a patient with HER2positive metastatic urothelial bladder cancer (mUBC)?
- Regulatory and reimbursement issues aside, what would you generally recommend as second-line therapy for a patient with HER2-positive (IHC 3+) mUBC whose disease progresses on first-line enfortumab vedotin/pembrolizumab? How, if at all, would your approach vary by agent(s) received and patient performance status?

Discussion Question

 Have you or would you administer trastuzumab deruxtecan to a patient with HER2-low (IHC 1+ or 2+) mUBC?

Discussion Questions

- Regulatory and reimbursement issues aside, what would you generally recommend as second-line therapy for a patient with mUBC with an FGFR3 mutation whose disease progresses on first-line enfortumab vedotin/pembrolizumab? How, if at all, would your approach vary by agent(s) received and patient performance status?
- What adverse events are commonly associated with erdafitinib? How can they be prevented and how should they be managed when they occur?

We are taking a short break!

The program will resume at 9:45 AM ET

Up Next...

Drs Natalie S Callander and Thomas Martin discuss the management of multiple myeloma

